The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer.
 
Yuan Yuan
Consulting or Advisory Role - BCI Pharma; Diiachi; Eisai; Genentech; Guardant Health; Immunomedics; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Genentech; Immunomedics; Merck; Novartis; Pfizer
Research Funding - Eisai; Genentech; Merck; Novartis; Pfizer; Puma Biotechnology
Expert Testimony - Novartis
 
Susan Elaine Yost
No Relationships to Disclose
 
Paul Henry Frankel
No Relationships to Disclose
 
Christopher Ruel
No Relationships to Disclose
 
Mireya Murga
No Relationships to Disclose
 
Aileen Tang
No Relationships to Disclose
 
Norma Martinez
No Relationships to Disclose
 
James Ross Waisman
No Relationships to Disclose
 
Daphne B. Stewart
No Relationships to Disclose
 
Niki Himat Patel
No Relationships to Disclose
 
Joanne E. Mortimer
Consulting or Advisory Role - Eisai; Eisai; GlaxoSmithKline; Karyopharm Therapeutics; Mesoblast; Puma Biotechnology